September 2026 Biopharma Hedge Fund Stock Picks: VRDN and 2 More
Sep 30
3 min read
For September 2026, our Hedge Fund Stock Picks highlight three biopharma companies with different clinical, commercial, and catalyst risks: Viridian Therapeutics (VRDN), a second pick with an emerging kidney-disease program, and a third with a pivotal eye-disease assessment ahead. Each of these is a biopharma-focused hedge fund consensus favorite, with 11 of 36 top biopharma hedge fund holders in VRDN, 9 in second pick, and 8 in third pick, which puts all of these above or near the top 10% of public smid-cap biopharma companies, an important validation of the quality of the company and its therapeutic assets.
